Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Bulletin of Experimental Biology and Medicine, 2017
62 Immunotherapy resistance Although immune checkpoint blockade (ICB) therapies (e.g., anti-PD-1/PD-L1, anti-CTLA-4 antibodies) have revolutionized cancer treatment, both primary and acquired resistance remain major challenges (Fig
3 For extra glow care, layer once more on areas of concern
[Sidebar discussion: is there a market to develop products and services for the longevity economy to meet the needs of people who are less affluent, older, etc
US$ 29.36
US$ 29.67
US$ 20.60
US$ 23.65
US$ 23.98
